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Summary: The perfonnance of different solid-phase luminescence immunoassays has been documented using
four different assay concepts. These are CELIA (chemilüminescence immunoassay), SPALT (solid-phase
antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric la-
belled second-antibody assay). CELIA is analogous to a solid-phase radioimmunoassay and uses a labelled
antigen, SPALT and ILSA use a labelled second (species-specific) antibody and ILMA a labelled substance-
specific antibody, i.e. analogous to the immunoradiometric assay. Both bioluminescent and chemiluminescent
labels have been used. Pyruvate kinase was used for bioluminescence and diazoluminol and N-(4-amino-
butyl)-N-ethyl isoluminol hemisuccinamide for chemilüminescence. Relevant quality-control parameters and
reference ranges have been given for the optimised assays. Assays described are: thyroxine, thyroxine binding
globulin, Cortisol, caeruloplasmin, ferritin and Oreactive protein.
Luminescence immunoassays with coefficients of Variation comparable with fadioimmunoassay have been
designed, values of ünder 5% being obtainable within the working ränge of the assay.
Beurteilung von vier verschiedenen Lumineszenz^Immunoassays:
CELIA (chemiluminescent immunoassay),
SPALT (solid-phase antigen luminescence technique),
ILMA (immunoluminometric assay) und
ILSA (immunoluminometric labelled second antibody).
Eine kritische Untersuchung von Makro-Festphasen zum Gebrauch in Immunoassay-Systemen, Teil III1)
Zusammenfassung: Die Entwicklung und Durchführung von Lumineszenzimmunoassays werden am Beispiel
von vier verschiedenen Assaykonzepten aufgezeigt. Der CELIA (Chemilumineszenzimmunoassay) verwen-
det markiertes Antigen, SPALT (Sqlid-Phase Antigen Lumineseence Technique) and ILSA (Immunolumino-
metric Labelied Second-Antibody Assay) markierten Spezies-spezifischen „zweiten" Antikörper und der
ILMA (Immunölummometric Assay) Substanz-spezifischen Antikörper, die markiert sind. Sowohl Biolumi-
neszenz (Pyruvatkinase)- als auch Chemilürnineszenz (Diazoluminol und N-(4-Aminobutyl)-N-ethyl-isolu-
') Part I: J. Clin. Chem. Clin. Biochem. 2/, 789-787. Part II: J. Clin. Chem. Clin. Biochem. 22, 337-347.
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minol-hemisuccinamid)-Markierungen wurden verwendet und gegenübergestellt. Qualitätskontrollkenngrö-
ßen und Referenzbereiche im Serum werden für die optimierten Assays ermittelt. Es werden Lumineszerizim-
munoassays für die folgenden Substanzen beschrieben: Thyroxin, thyroxin-bindendes Globulin, Cortisol,
Ferritin, Caeruloplasmin und C-reactives Protein.
Die entwickelten Lumineszenzimmunoassays zeigen dem Radioimmunöassay vergleichbare (Variationskoeffi-
zienten mit Werten unter 5% im relevanten Bereich.
Introduction
This third and final part of a study upon solid phases
for immunoassay describes the assays which have
been developed from the experiments described in
the first two parts (l, 2). Both functional and non-
functional assay Systems have been presented äs well
äs comparisons between different assay Systems for
the same analyte.
The assays described include those using labelled an-
tigens and labelled first or second antibodies. The
labels used are: diazoluminol and N-(4-aminobutyl)-
N-ethyl isoluminol hemisuccinamide, the latter be-
ing coupled via an active ester of N-hydroxysuccin-
amide. The synthesis of the labels has already been
described (2). The assays represent different ana-
lytes (haptens or peptides) and methods. Where ap-
plicable, assays which have already been introduced
into the routine laboratory are presented with rele-
vant quality-control parameters and comparisons




Antibodies to human liver and spieen ferritins were purchased
from Atlanta (Pelfreez), Heidelberg; Proma (Seward), Augsburg;
Boehringer-Ingelheim (DAKO), Ingelheim; these being the dis-
tributors in the FRG. Antibodies to human C-reactive protein and
human thyroxine binding globulin were obtained from Proma and
Boehringer-Ingelheim.
Antibodies to caeruloplasmin were purchased from Behring-
werke, Marburg a. d. L., FRG, whereas those for Cortisol and thyr-
oxine were donations from Dr. Mario Pazzagli, Firenze, Italy and
the Fa. Henning Berlin GmbH respectively.
Donkey anti-rabbit IgG was purchased from Wellcome Diagnos-
tika, Burgwedel, FRG and rabbit anti-sheep IgG from Boehringer
Ingelheim.
Standard materials
Ferritin Standards were obtained from Travenol-Clinical Assays,
Munich, FRG, C-reactive protein serum Standard from Behring-
werke, thyroxine and Cortisol Standards from Henning Berlin and
Diagnostic Products Corporation (Hermann Biermann, Bad Nau-
heim, FRG) respectively. Human transferrin was purchased from
Behringwerke, human caeruloplasmin from Serva, Heidelberg,
FRG or Sigma, Munich, human thyroxine binding globulin being
a gift from Prof. K. Hörn and Dr. R. Gärtner, Munich.
Equipment
The luminometers used were either the LKB-1251 (LKB Instru-
ments, Gräfelfing, FRG) or the LB-950 (Laboratorium Prof. Dr.
Berthpld, Wildbad, FRG). The LKB-1251 was a 25-sample semi-
automatic Instrument with microprocessor, the LB-950 had a 300
sample capacity and was also microprpcessor controlled. Both in-
struments were at the time of the experiments not able to process
data fully so that an off-line data-processing with a desk-top com^
puter (CBM 8032 — Commodore Business Machines, Neu-Isen-
bürg, FRG) and spline function Programme was necessary.
Methods
CELIA — chemiluminescent immunoassay
This type of assay is analogous to a solid-phase radioimmunoassay
in which the first antibody was coupled to a polystyrene ball (1)
and in which the tracer was an antigen labelled with N-(4-amino-
butyl)-N-ethyl isoluminol hemisuccinamide instead of a radioac-
tive marker. Table l shows the assay flow sheet for a TBG CE-
LIA.
Tab. 1. Thyroxine binding globulin CELIA flow sheet.
50 sample or Standard
200 assay buffer (0.05 mol/1 Tris^HCl
containing 2.50 g/l bovine serum albumin, pH 7.4
l sheep anti human TBG coated ball
Incubate at ambient temperature for 30 min
.V ·..·., ' r
50 diazoluminol labelled TBG (l: 100 dilution*)
Incubate äs above and wash with 2 x l ml 0.15 mol/1 NaQ
containing 0.15 ml/l Tween 20.
Transfer balls to measuring euvettes and load luminometer.
The light initiation Step is identical with that shown in table 2.
* The diazotisation was analogous to the methpd described in Lc.
(2), replacing the second antibody with thyroxine binding glo-
bulin. The dilution factor given here is the further dilution of
the TBG-diazoluminol. The amount of label added to each tube
was approximately 100 ng.
ILMA - immunoluminometric assay
The ILMA is analogous to the IRMA (immunoradiometric assay)
(3) and is especially suited for assays where the antigen is either
unavailable or prohibitively expensive so that a SPALT (see be^
low) assay is out of the question. Several antibody-pairs were test-
ed until a suitable combination was found. Table 2 shows an assay
flow sheet for a ferritin ILMA.
ILSA — immunoluminometric labelled second^antibody assay
The ILSA is identical with the ILMA, but with one exception, and
that is that a labelled second antibody is used in addition to the
two substance-specific antibodies used in the ILMA. This assay
was only used in cases where diazoluminol was used for labelling
the antibodies, in Order to achieve maximal sensitivity. Table 3
shows a flow sheet for a C-reäctive protein ILSA.
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Tab. 2. Ferritin ILMA flow sheet.
20 μΐ sample or Standard
200 μΐ assay buffer (0.025 mol/1 phosphate/0.025 mol/1 Tris-HCl
containing 0.5 ml/l Tween 20 and l .25 g/l bovine serum
albumin, pH 7.4
l goat anti human liver ferritin coated ball
Incubate for 3 h on a horizontal rotator (180 min""1)
Wash with 2 x 5 ml 0.15 mol/1 NaCl
containing 0.15 ml/l Tween 20
200 μΐ N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide
labelled rabbit anti human ferritin (1:500 dilution)*
Incubate and wash s above and transfer balls to measuring
cuvettes.
Add 250 μΐ 0.15 mol/1 NaCl and load luminometer. Initiale light
reaction with l mol/1 NaOH, 2 mg/1 microperoxidase-MP 11
and 0.15 mol/1 H2C>2 (100 μΐ + 10 μΐ-f- 360 μΐ respectively).
Integrate the light signal over 20 s
* This represents the dilution of the labelled antibody after cou-
pling to N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide
using the same method for labelling donkey anti rabbit IgG -
see I.e. (2).
Tab. 3. C-reactive protein ILSA flow sheet.
10 μΐ sample or Standard, 1:10 dilution in assay buffer
(0.05 mol/1 Tris-HCl containing 2.5 g/l bovine serum albumin,
pH 7.6)
200 μΐ assay buffer
l sheep anti human C-reactive protein coated ball
Incubation 60 min at 37 °C in a water bath, followed by 2 x 5 ml
wash with assay buffer
200 μΐ rabbit anti human C-reactive protein (l :500 dilution)
Incubate and wash s above
300 μΐ diazoluminol labelled donkey anti rabbit serum
(1:60 dilution*)
Incubate s above, wash and transfer balls to measuring cuvette.
Load luminometer and proceed s in table 2.
* represents the further dilution of the labelled antibody s pre-
pared in I.e. (2).
Tab. 4. Caeruloplasmin SPALT flow sheet.
50 μΐ sample or Standard, l :25 dilution in assay buffer (see
table 2)
150 μΐ rabbit anti caeruloplasmin (] :500 dilution)
Incubate at ambient temperature for 10 min*
l human caeruloplasmin coated ball
Incubate for 50 min on horizontal rotator (180 min"1) at ambient
temperature
Wash with 2 x 5 ml 0.15 mol/1 NaCl containing 0.15 ml/l
Tween 20
200 μΐ donkey anti rabbit IgG labelled with N-(4-aminobutyl)-N-
ethylisoluminol hemisuccinamide (1:150* dilution)
Incubate for 60 min on rotator and wash s above.
Transfer balls to measuring cuvettes and proceed s in table 2.
+ represents dilution of labelled antibody s prepared in I.e. (2).
* this stcp improved the precision of the assay.
Tab. 5. Thyroxine SPALT flow sheet.
25 μΐ sample or Standard
150 μΐ assay buffer (0.05 mol/I Tris-HCl containing
1.58 mmol/1 8-anilino-l-naphthalene sulphonic acid
(ammoniuni salt), pH 7.5
100 μΐ rabbit anti thyroxine (l :500 dilution)
Incubate for 60 min at ambient temperature
l Transferrin-thyroxine coated polystyrene ball*
Incubate s above, but on horizontal rotator and wash with
2 x l ml wash buffer (0.05 mol/1 Tris-HCl containing
0.15 ml/l Tween 20, pH 7.5)
300 μΐ donkey anti rabbit IgG labelled with either pyruvate kinase
or diazoluminol (l :50 dilution)
Incubate for 60 min on horizontal rotator and wash with l ml
wash buffer followed by l ml 0.15 mol/1 NaCl. Transfer balls to
measuring cuvettes and proceed with the light initiation Step
s in table 2.
* Synthesis of the thyroxine-transferrin conjugate has been de-
scribed in I.e. (2).
SPALT - solid phase antigen luminescence technique
The SPALT principle has been described in detail elsewhere (4,
5), and only the v riatipns are briefly described here. The SPALT
assay can be set up s eithef a competitive or sequential assay,
depending upon whether the solid phase antigen is added together
with the first antibody and sample or after a pre-incubation of first
antibody and sample. Tables 4 and 5 show competitive and se-
quential SPALT assays for caeruloplasmin and thyroxine respec-
tively.
Assay semi-automation
The assays were originally set up in 55 x 12 mm polystyrene tubes
which increased the time needed for pipetting and wash Steps s
each tube had to be processed seperately. To increase throughput
and reduce the workload assays were set up in either 20 or 60 well
trays (cf. Abbott hepatitis kits). The wash Steps were carried out
using a Pentawash multiple wash device (Abbott Laboratories)
where 5 wells were washed simultaneously with 5 ml wash solu-
tion. The anti gen-antibody reaction was speeded up by incubating
the trays on a horizontal rotator at 180 min"·1.
The improvement in precision, shortening of assay time and semi-
automation of all methods more than compensated for the addi-
tional cost of buying the equipment. Moreover, the trays could be
re-used after washing without the precision and accuracy of the
assay being influenced.
Results
Comparison of a CELIA and ILMA for thyroxine
binding globulin (TBG)
Figure l shows Standard curves for a TBG-CELIA
and a TBG-ILMA. Table 6 shows the relevant assay
and quality control data. The antibody bound to the
solid phase was the same in each case s was the lab-
el used, in this case diazoluminol. The TBG used for
labelling was identical with that used for making up
the Standards in both assays.
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Tab. 6. Comparison of thyroxine binding globulin (TBG) CELIA
and ILMA using diazoluminol äs label.
0 2.5 5 10 20 40
Thyroxine binding globulin [mg/U
Fig. l. Comparison between the thyroxine binding globulin CE-
LIA (ü—Q) and ILMA (O—O). Both assays were mea-
sured on an LKB 1251 luminometer, the Ordinate repre-
senting the integral of the light curve over 20 seconds.
Each Standard curve point is shown with the mean and 2
Standard deviation (95% confidence-) limits.
Comparison between labelling using ILMA and IL-
SA for ferritin äs examples
Figure 2 shows three Standard curves using identical
starting reagents. For the ILSA the second antibody
(donkey anti-rabbit IgG) was labelled with diazolu-
minol (2), for the ILMAs both diazoluminol and N-
(4-aminobutyl)-N-ethyl isoluminol hemisuccinam-
ide were used to label the second anti-ferritin anti-
body. Table 7 shows relevant data from all three
curves, here with special reference to the sensitivity
(Iowest detectable antigen level).
Comparison of different pH values to initiale, the light
reaction using a serum Cortisol SPALT äs an example
Table 8 shows a comparison between three cortisol
SPALT assays set up at the same time with the same
reagents. The difference between the assays is that
öne is oxidised at pH 8.6 to initiate the light reaction,
the second with sodium hydroxide, directly after ad-
dition, and the third, after the solid phase has been
left in contact with sodium hydroxide for 2 h. The
assay flow sheet up until the light-reaction Step is
shown in table 9.
Parameter
Assay type













Zero Standard (B0) 250 37
5 mg/1 Standard (B5) 150 65







Hl (14 ±3) (mean ± s.d.) above80 13.6
H2 (26 ± 5) above 80 27.3
H3(37±6) above 80 35.9
Correlation data*** with RIA
No. ofsamples — 89
Correlation cofficient r - 0.985
Intercept ayx (mg/1) - - 2.74
Slope byx - 0.976
Range of values used (mg/1) - 10-43
+ Both assays were performed simultaneously.
++ Expressed äs mV · 20 s (integral)
* These values represent the dynamic ränge for the CELIA
and ILMA respectively.
** The CELIA, although giving a Standard curve, was unäble to
measure serum samples, and was therefore abandonne'd.
Target values in brackets. N
*** The correlation coefficient and related data was determined
from a comparison with the Henning TBG-RIA, resuits from
6 assays being used. The RIA values were entered äs x.
7000-
Ö "10 50 100 " "500
Ferritin t/ig/l'ü
1000
Fig. 2. Comparison of three ferritin assays using diazoluminol
( — ILSA; ·—· ILMA) and N-(4-aminobutyl)-N-
ethyl isoluminol hemisuceinamide (O-^O ILMA) labelled
antibodies. Please note that the fccales are not linear. The
Symbols and their significance are äs in figure 1.
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Tab. 7. Comparison of ferritin ILMA and ILSA using diazolu-
minol and N-(4-aminobutyl)-N-ethylisoluminol hemisuc-
cinamide (ABEI-H) s labels - relevant assay data.







Zero Standard (B )
5 ̂ g/1 Standard (B5)
1 C^g/l Standard (B i o)
200 μg/l Standard (B2oo)









Control serum values ̂ g/l)**
D4 - target value 16 ± 1.9
D5 - target value 53 ± 4.2














































+ Integral over 20 s, given in 1000 "Berthold light units"
++ Expression of the dynamic r nge of the assay
* Represents the actual spread of counts between the lowest
and highest Standard.
** Values given s mean ± l Standard deviation. The values giv-
en are the mean of duplicate values.
Tab. 8. Effect of pH and exposure time to sodium hydroxide on
the light emission using the Cortisol SPALT s an exam-
ple.
Parameter pH8+ pH 13+ pH 13+
immediate after 2 h
Light emission
of zero Standard (B )
Light emission of
unspecific binding ( B)
Light emission of


































Results in 1000 "Berthold Light Units"
All assays were set up at the same time. The results in column
2 were obtained when the tubes were processed directly after
NaOH addition, those in column 3 when the light Initiation
Step took place 2 h after NaOH addition. The results in co-
lumn l were obtained when 0.5 mol/1 phosphate buffer re-
placed the l mol/1 NaOH.
Results cxpressed are the mean of duplicate tubes.
10 μΐ sample or Standard
200 μΐ rabbit anti Cortisol, l :4000 in assay buffer
(0.1 mol/1 phosphate containing 0.1 mol/1 sodium salicylate,
pH 7.5)
l cortisol-3-carboxymethyloxime-ovalbumin coated ball
Incubate on horizontal rotator (180 min"1) for 35 min at ambient
temperature
Wash with 2 x 5 ml 0.15 mol/1 NaCl containing 0.15 ml/l
Tween 20
200 μ! N-(4-aminobutyl)-N-ethylisoluminol hemisuccinamide
labelled donkey anti rabbit IgG (l: 180 dilution*)
Incubate s above, but for 45 min, wash s above and proceed s
described in table 2 for the ball-transfer and light-initiating
Steps
* See table 4.
Comparison between pymvate kinase and diazolu-
minol s labelfor the second antibody using a thyrox-
ine SPALTE an example
The assay flow scheme has already been shown in
table 5. Figure 3 shows Standard curves for both as-
says, the relevant assay data being shown in table 10.
-3600
C^ 20 40 80
Thyroxine Ιμο/l)
160 320
Fig. 3. Comparison of use of a bioluminescent (pyruvate kinase
•—·) label and a chemiluminescent label in a thyroxine
SPALT. Both assays were measured on an LKB 1250
luminometer, the left-hand Ordinate showing the chemi-
luminescent signal s 20 s integral, the right-hand Ordinate
the slopc of the ATP-generation curve, expressed s mV/
min.
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Tab. 10. Comparison between a chemiluminescent and biolumi-











12 nmol/1 Standard (Bi2)
4 1 0 nmol/1 Standard (64 10)

















Qua l i ty control
Serum A (27 ± 5) nmol/1**
Serum B (74 ±10)





















+ Counts for Assay l mV · 20 s (integral), for Assay 2 mV/min
(slope)
++ Expression of the assay dynamic r nge
* Assays set up at the same time and measured manually on an
LKB 1250 Luminometer (see I.e. (1) and (2))
** Target values ± l Standard deviation - results are the mean
of duplicate determinations.
Clinical examples of routine luminescence immu-
noassay s - datafrom a caeruloplasmin SPALT, a C-
reactive protein ILSA and a ferritin ILMA
Figures 4 and 5 show typical Standard curves for cae-
ruloplasmin and C-reactive protein respectively. The
label for the caeruloplasmin SPALT was N-(4-ami-
nobutyl)-N-ethyl isoluminol hemisuccinamide, for
C-reactive protein, diazoluminol. In both cases, the
second antibody was labelled donkey anti-rabbit
IgG. Table 11 shows clinical data obtained for differ-
ent patient groups. The correlation between the fer-
ritin assay here described and the radioimmunoassay
used s its predecessor in the routine determination
was excellent, (n = 91, r = 0.992, ayx = 0.071 and
byx = 0.999) when the same Standards were used in
each assay. Here the radioimmunoassay values were
entered s x, those from the ILMA s y. The r nge of
the values used for this calculation were 5-570 μg/l








0 0.08 0.16 0.32 0,64 1.25
CoeruloplQsmin [g/l]
2.5
Fig. 4. Caeruloplasmin SPALT measured on the Berthold LB-
950 luminometer. The ordinate represents the 20 s inte-
gral, expressed here in "Berthold light units" x 10$, s
this luminometer employs phpton counting teehniques














£Fig. 5. C-reactive protein ILSA, using a diazoluminol labelled se-
cond antibody (donkey anti-rat?bit IgG). This assay was
measured on an LKB 1251 luminometer, the ordinate
showing the 20 s integral value.
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Tab. 11. Assay parameters and values from three experimental



















Reference ränge 0.15-0.65 g/l under 5 mg/1 30-300 g/I
(serum)
Assay working 0.15-1.25 g/l 2-160 mg/1 5-1000 g/l
range++
Mean precision 5.8 (n = 205) 4.2 (n = 99) 4.3 (n = 1254)
(%)·"·+











































































+ CP = caeruloplasmin, CRP = C-reactive protein, LF = liver
ferritin, ABEI-H = N-(4-aminobutyI)-N-ethyl isoluminol
hemisuccinamide
++ Range in which the mean precision is under 10%
'++ Actual precision within the working ränge — mean of all pa-
tients (n = . . .)
* Values lying below or above the established reference ränge.
** Pre-operative values - only patients with surgically con-
firmed tumours used in this analysis.
Discussion
The aim of this paper has been to put into practice
some of the experiments performed in the first two
parts of this series (l, 2). A comparison of both lab-
els and methods has been made using a wide variety
of antigens äs ligands. Detailed clinical trials and
evaluation results have been avoided, results being
limited to a few assays, especially those shown in ta-
ble 11.
The future of the luminescence immunoassay lies in
its field of application, especially where its role äs a
practical alternative to routine radioimmunoassays is
concerned. The assays presented here represent the
whole gamut of molecular size and concentration
found in in-vitro clinical chemistry and endocrinol-
ogy.
The results of the comparison between a CELIA and
ILMA using the same label and components (diazo-
luminol and immobilised sheep anti TBG) shows the
relative sensitivity and working ränge of the two as-
say types, here for thyroxine binding globulin. The
larger working ränge of the ILMA agrees with the
findings of Hunter (6) who compared radioimmu-
noassays and immunoradiometric assays for sensitiv-
ity and working ränge. The TBG CELIA, although
giving a dose response curve when the Standards
were dissolved in a buffer matrix, was unable to be
used for measuring serum samples, where all values
lay above the highest Standard. The combination of
the relatively large sample volume (50 ) and con-
tact between serum and label may be a crucial factor
with the CELIA, äs the TBG ILMA, where a much
smaller sample (l ) was used, and where serum and
label did not come into contact, measured correctly.
Similar problems were encountered with a thyroxine
CELIA using larger serum volumes (50 ) and low-
titer low affinity antibodies (Gadow, unpublished re-
sults).
The comparison between the different labels is well
demonstrated in the case of the ferritin assays (table
7, figure 2). Although the detection limits of free di-
azoluminol and N-(4-aminobutyl)-N-ethyI isolumin-
ol hemisuccinamide were similar (2), the N-(4-ami-
nobutyl)-N-ethyl isoluminol hemisuccinamide label
allowed an assay to be developed which was sensitive
enough for routine use. This was probably due to the
difference in the chemical coupling methods used,
the N-(4-aminobutyl)-N-ethyl isoluminol hemisucci-
namide active ester being under neutral and mild
reaction conditions, the diazo coupling taking place
in alkaline solution over a period of several hours.
The ferritin assays show the relative performance of
ILMA and ILSA using the same label (here diazolu-
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minol). The dynamic ränge of the N-(4-aminobutyl)-
N-ethyl isoluminol hemisuccinamide labelled ferritin
ILMA is far greater than that using diazoluminol äs
label. This is reflected in the ratio between the
number of counts in the highest Standard and those
in the zero Standard, (see tab. 7). This ratio was 54:1
for N-(4-aminobutyl)-N-ethyl isoluminol hemisucci-
namide labelled anti ferritin and only 4.9:1 for dia-
zoluminol labelled anti ferritin.
Various conditions have been described for the op-
timal conditions for light emission which ränge from
initiation at pH 8-9 (7) via pH 13 (4) to initiation
after Standing in alkaline solution for several minutes
(8) to a few hours (Kohen, personal communica-
tion). The cortisol SPALT (see tab. 8 and 9) was
used to compare the effect of pH and alkaline incu-
bation on the light Output. Although the signal in-
creases between pH 8 and pH 13 äs well äs between
pH 13 when measured immediately and after 2 h
Standing in sodiüm hydroxide, the signal to noise ra-
tio, expressed in terms of the zero Standard (Bö) and
unspecific binding (ÜB) increased only slightly.
The dynamic ränge of the assay, expressed äs the
light signal given by the zero Standard and that given
by the highest Standard, remained almost unchanged
between pH 8 and pH 13, and was noticably reduced
after prolonged alkaline incubation before light initi-
ation.
The values of the control sera lay within the expect-
ed limits for all assays.
The thyroxine SPALT was used to demonstrate the
use of bioluminescent and chemiluminescent labels.
The bioluminescent SPALT had a larger dynamic
ränge when compared with the diazoluminol labelled
assay, and was potentially more sensitive, äs can be
seen from the intercept values (tab. 10). Both assays
measured correctly in terms of the control sera. Re-
placement of the diazoluminol labelled second anti-
body by one labelled with N-(4-aminobutyl)-N-ethyl
isoluminol hemisuccinamide gave rise to a similar in-
crease in the dynamic ränge äs seen in the ferritin
ILMA, so that for the routine assay, N-(4-aminobu-
tyl)-N-ethyl isoluminol hemisuccinamide was chosen
äs label.
·· f
As stated above, the proof of the assays is in their
clinical routine application and examples have been
presented for ferritin, C-reactive protein and caeru-
loplasmin, all of which are the only routine assay for
these components. The results shown are taken from
projects on patients with tumours and with Crohn's
disease or ulcerative colitis (see tab. 11). The screen-
ing of blood donors is part of an ongoing routine
procedure, especially upon new and regulär donors.
The mean precision within the workiiig ränge, here
derived from compound precision profiles, was ac-
ceptable and comparable with commercial tests. A
further advahtage of these tests was their suitability
for paediatric use, the largest sample volume being
20 for ferritin.
One thing became clear when working with immobi-
lised antibodies, and that was the necessity for par-
tial purification of the native antisera before cou-
pling to the solid phase. This was effected by precipi-
tation of the -globulin fraction with 200 g/l polyeth-
ylene glycol (Mr 6000) with resolution of the precipi-
tate in 0.02 mol/1 phosphate buffer, pH 8. Sübse-
quent passage over a DEAE-cellulose column was
sufficient to give a product with acceptable purity.
To conclude, it has been shown that the application
of luminescence immunoassays in routine in-vitro
diagnosis is now possible, although the acceptance of
such assays still depends upon the commercialisation
of the methods.
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